143 related articles for article (PubMed ID: 37192745)
41. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.
Wang L; Zhang J; Yang X; Chang YW; Qi M; Zhou Z; Zhang J; Han B
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):301-7. PubMed ID: 23917306
[TBL] [Abstract][Full Text] [Related]
42. microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1.
Yang B; Diao H; Wang P; Guan F; Liu H
Bioengineered; 2021 Dec; 12(1):9094-9102. PubMed ID: 34654353
[TBL] [Abstract][Full Text] [Related]
43. Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma.
Qiao S; Zhang W; Su Y; Jiang Y
Front Oncol; 2022; 12():1037535. PubMed ID: 36591519
[TBL] [Abstract][Full Text] [Related]
44. Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.
Zhang Z; Chai C; Shen T; Li X; Ji J; Li C; Shang Z; Niu Y
Dis Markers; 2019; 2019():4782730. PubMed ID: 31565099
[TBL] [Abstract][Full Text] [Related]
45. IgG gene expression and its possible significance in prostate cancers.
Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Liao J; Ye Y; Xu X
Clin Transl Oncol; 2022 Oct; 24(10):1986-1997. PubMed ID: 35732871
[TBL] [Abstract][Full Text] [Related]
47. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
48. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
49. Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2.
Cheng J; Zhou J; Fu S; Fu J; Zhou B; Chen H; Fu J; Wei C
J Cell Mol Med; 2021 Apr; 25(8):4157-4165. PubMed ID: 33609069
[TBL] [Abstract][Full Text] [Related]
50. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
51. Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7.
Lopez-Beltran A; Cheng L; Blanca A; Montironi R
Anal Quant Cytol Histol; 2012 Apr; 34(2):61-5. PubMed ID: 22611760
[TBL] [Abstract][Full Text] [Related]
52. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
53. Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Roberto D; Selvarajah S; Park PC; Berman D; Venkateswaran V
Prostate; 2019 Nov; 79(15):1777-1788. PubMed ID: 31503357
[TBL] [Abstract][Full Text] [Related]
54. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
[TBL] [Abstract][Full Text] [Related]
55. A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.
Hu K; Hu X; Duan Y; Li W; Qian J; Chen J
Front Med (Lausanne); 2022; 9():815541. PubMed ID: 35783639
[TBL] [Abstract][Full Text] [Related]
56. TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.
Gao HT; Yang Z; Sun H; Zhang Y; Wang Z; Liu WY; Wen HZ; Qu CB; Wang XL
Am J Transl Res; 2023; 15(2):779-798. PubMed ID: 36915769
[TBL] [Abstract][Full Text] [Related]
57. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
58. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
60. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
